Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus

BACKGROUND: Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia. Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular interest for the prevention of accelerated cognitive decline, because...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: Biessels, Geert Jan, Janssen, Jolien, van den Berg, Esther, Zinman, Bernard, Espeland, Mark A., Mattheus, Michaela, Johansen, Odd Erik
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5769408/
https://ncbi.nlm.nih.gov/pubmed/29334906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-018-1014-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars